Biophytis SA (FR:ALBPS) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biophytis SA has received FDA approval to commence a phase 2 clinical study of BIO101 for obesity, focusing on muscle strength and mobility improvements. Anticipated to start in mid-2024 in the USA, the study’s prelim results are expected in 2025. The company is actively seeking funding and partnerships to advance this study in the growing obesity treatment market.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.